Edition:
India

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

3.18EUR
2:56pm IST
Change (% chg)

€-0.03 (-0.93%)
Prev Close
€3.21
Open
€3.24
Day's High
€3.24
Day's Low
€3.15
Volume
27,154
Avg. Vol
70,253
52-wk High
€3.79
52-wk Low
€2.40

Chart for

About

Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for... (more)

Overall

Beta: -0.15
Market Cap(Mil.): €186.79
Shares Outstanding(Mil.): 56.43
Dividend: --
Yield (%): --

Financials

BRIEF-Transgene Q1 Operating Revenue Stable At 1.8 Million Euros

* TRANSGENE: €35.6 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018

26 Apr 2018

BRIEF-Transgene Says PCPV Most Promising Therapeutic Candidate Amongst Evaluated Poxviridae

* PCPV WAS FOUND TO BE MOST PROMISING THERAPEUTIC CANDIDATE AMONGST POXVIRIDAE EVALUATED BY TRANSGENE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

18 Apr 2018

BRIEF-Transgene To Announce Major Clinical Results In 2018

* TRANSGENE TO ANNOUNCE MAJOR CLINICAL RESULTS IN 2018 AND ACHIEVE PROMISING PROGRESS ON ITS NEW ONCOLYTIC VIRUSES

21 Mar 2018

BRIEF-Transgene Says ‍First Patient Dosed In China In Trial Of T101​

* ‍FIRST CHRONIC HEPATITIS B PATIENT DOSED IN CHINA IN A PHASE 1 TRIAL OF T101​

17 Jan 2018

BRIEF-Transgene Announces ‍Dosing Of First Patient In Phase 2 Trial Of TG4010 Evaluation ​

* ‍FIRST PATIENT DOSED IN A PHASE 2 TRIAL WITH TRANSGENE'S TG4010 + NIVOLUMAB + CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF LUNG CANCER (NSCLC)​

16 Jan 2018

Earnings vs. Estimates